Analysis of Clinical Efficacy and Prognostic Factors of Endocrine Therapy in Patients with HR+/HER2-Advanced Breast Cancer
Objective To observe the clinical efficacy of endocrine therapy in patients with HR+/HER2-advanced breast cancer and to explore the factors affecting prognosis.Methods A total of 120 patients with HR+/HER2-advanced breast cancer were enrolled,and all patients were given endocrine therapy,the treatment effect after treatment was evaluated,and the occurrence of adverse events was recorded.The patients were followed up for 1 year,and the patients were divided into poor prognosis group and good prognosis group according to whether patients had recurrence and metastasis.Patient data were collect-ed,and univariate and multivariate logistic regression was analyzed for factors affecting the prognosis of HR+/HER2-advanced breast cancer patients.Results Of the 120 patients with HR+/HER2-advanced breast cancer,2 cases(1.67％)reached CR and 15 cases(12.50％)reached PR after treatment.After 1 year of follow-up,21 patients had recurrence or metastasis,and 99 pa-tients had no recurrence or metastasis.The incidence of neutropenia in adverse events was 97.50％(117/120),the incidence of leukopenia was 93.33％(112/120).Among which grade 2-3 accounted for the highest proportion,and the adverse events could be alleviated by adjusting the dosage.Among the non-hematologic adverse events,fatigue was the most common at 23.33％(28/120),followed by oral mucositis at 9.17％(11/120).There were significant differences in age,visceral metastasis,and number of previous chemotherapy lines between different prognostic groups(P＜0.05).Multivariate logistic regression analysis showed that age,visceral metastases,and prior 2-3 lines of chemotherapy were factors affecting the prognosis of patients with HR+/HER2-advanced breast cancer(P＜0.05).Conclusion Endocrine therapy is safe and effective in patients with HR+/HER2-ad-vanced breast cancer,and age,visceral metastasis and previous 2-3 lines of chemotherapy are the factors affecting the prognosis of patients.
HR+/HER2-advanced breast cancerEndocrine therapyPrognosisEfficacy
NETL
NSTL
万方数据
